← Back to Clinical Trials
Recruiting NCT07793045

NCT07793045 Binaural Beats Stimulation for Adults With Attention-Deficit/Hyperactivity Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07793045
Status Recruiting
Phase
Sponsor California State University, San Bernardino
Condition Attention-Deficit/Hyperactivity Disorder (ADHD)
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-03-03
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Music-Based Binaural Beats StimulationMusic Listening Without Binaural Beats

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-03-03 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will evaluate the feasibility and potential effects of a six-week, music-based binaural beats stimulation program in adults with attention-deficit/hyperactivity disorder (ADHD). Forty adults with ADHD will be randomly assigned to either a binaural beat stimulation group or a control group. Both groups will attend 12 supervised listening sessions over six weeks and listen to similar music for 20 minutes per session; however, only the intervention group's music will contain embedded binaural beats. Cognitive assessments will be completed before and after the intervention to evaluate changes in attention and memory. Session attendance and participant retention will also be examined to assess the feasibility and acceptability of the program.

Eligibility Criteria

Inclusion Criteria: 1. Adults aged 18 to 55 years 2. Previous diagnosis of attention-deficit/hyperactivity disorder (ADHD) made by a qualified healthcare professional and supported by the Adult ADHD Self-Report Scale, version 1.1 (ASRS-v1.1) 3. Willing to wear headphones during the listening sessions 4. Able and willing to attend 12 listening sessions conducted twice weekly over six weeks - Exclusion Criteria: 1. Anticipated absence from the study area for more than seven days during the two-month study period 2. Uncorrectable hearing impairment that would prevent adequate delivery of music through headphones 3. Acute psychiatric condition, such as depression 4. Intellectual or developmental disability that could interfere with study participation 5. Acute medical condition resulting in sensory impairment 6. Initiation of, or a change in dosage of, stimulant, antipsychotic, or analgesic medication within the previous month 7. Anticipated change in stimulant, antipsychotic, or analgesic medication during the study period

Contact & Investigator

Central Contact

Zhaojing Chen, Ph.D.

✉ zhaojing.chen@csusb.edu

📞 909-537-5358

Frequently Asked Questions

Who can join the NCT07793045 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Attention-Deficit/Hyperactivity Disorder (ADHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07793045 currently recruiting?

Yes, NCT07793045 is actively recruiting participants. Contact the research team at zhaojing.chen@csusb.edu for enrollment information.

Where is the NCT07793045 trial being conducted?

This trial is being conducted at San Bernardino, United States.

Who is sponsoring the NCT07793045 clinical trial?

NCT07793045 is sponsored by California State University, San Bernardino. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology